At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)drug
Likely dose
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating Triamcinolone Acetonide 10 mg/mL (Kenalog-10) for Alopecia Areata. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesUnited States
CollaboratorsNational Alopecia Areata Foundation
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedJun 2007
Primary CompletionJun 2009
Study CompletionMar 2011
TodayJul 2026
First PostedJun 11, 2007
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2009
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.1 years ago
Interventions
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)drug
Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection